Ignite Creation Date:
2025-12-24 @ 2:23 PM
Ignite Modification Date:
2026-01-01 @ 4:38 PM
Study NCT ID:
NCT04044859
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2025-03-13
First Post:
2019-07-03
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
ADP-A2M4CD8 as Monotherapy or in Combination With Either Nivolumab or Pembrolizumab in HLA-A2+ Subjects With MAGE-A4 Positive Tumors (SURPASS)
Sponsor:
Adaptimmune
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2019-08-20
Start Date Type:
ACTUAL
Primary Completion Date:
2025-12-23
Primary Completion Date Type:
ESTIMATED
Completion Date:
2037-04-30
Completion Date Type:
ESTIMATED
First Submit Date:
2019-07-03
First Submit QC Date:
None
Study First Post Date:
2019-08-05
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-03-11
Last Update Post Date:
2025-03-13
Last Update Post Date Type:
ACTUAL